AR033300A1 - Compuestos de cefem - Google Patents

Compuestos de cefem

Info

Publication number
AR033300A1
AR033300A1 ARP020101603A ARP020101603A AR033300A1 AR 033300 A1 AR033300 A1 AR 033300A1 AR P020101603 A ARP020101603 A AR P020101603A AR P020101603 A ARP020101603 A AR P020101603A AR 033300 A1 AR033300 A1 AR 033300A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
protected
compound
formula
Prior art date
Application number
ARP020101603A
Other languages
English (en)
Spanish (es)
Original Assignee
Fujisawa Pharmaceutical Co
Wakunaga Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR4690A external-priority patent/AUPR469001A0/en
Priority claimed from AUPR5834A external-priority patent/AUPR583401A0/en
Application filed by Fujisawa Pharmaceutical Co, Wakunaga Pharma Co Ltd filed Critical Fujisawa Pharmaceutical Co
Publication of AR033300A1 publication Critical patent/AR033300A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
ARP020101603A 2001-05-01 2002-04-30 Compuestos de cefem AR033300A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR4690A AUPR469001A0 (en) 2001-05-01 2001-05-01 Cephem compounds
AUPR5834A AUPR583401A0 (en) 2001-06-20 2001-06-20 Cephem compounds

Publications (1)

Publication Number Publication Date
AR033300A1 true AR033300A1 (es) 2003-12-10

Family

ID=25646666

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101603A AR033300A1 (es) 2001-05-01 2002-04-30 Compuestos de cefem

Country Status (19)

Country Link
US (1) US7179801B2 (enExample)
EP (1) EP1392704B1 (enExample)
JP (1) JP4251873B2 (enExample)
KR (1) KR20030090794A (enExample)
CN (1) CN1522259A (enExample)
AR (1) AR033300A1 (enExample)
AT (1) ATE318269T1 (enExample)
BR (1) BR0209452A (enExample)
CA (1) CA2446099A1 (enExample)
DE (1) DE60209341T2 (enExample)
ES (1) ES2254671T3 (enExample)
HU (1) HUP0304042A2 (enExample)
MX (1) MXPA03010002A (enExample)
NO (1) NO20034824L (enExample)
NZ (1) NZ529887A (enExample)
PL (1) PL366507A1 (enExample)
RU (1) RU2003134629A (enExample)
TW (1) TWI224599B (enExample)
WO (1) WO2002090364A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4448821B2 (ja) * 2002-10-30 2010-04-14 アステラス製薬株式会社 セフェム化合物
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE602004026451D1 (de) * 2003-09-18 2010-05-20 Astellas Pharma Inc Cephem-verbindungen
WO2005044819A1 (en) * 2003-10-28 2005-05-19 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
EP1721906A4 (en) * 2004-03-05 2008-02-27 Shionogi & Co METHYLCEPHEM COMPOUND 3-PYRIDINIUM
JP2009530228A (ja) * 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
HK1200096A1 (en) 2011-09-09 2015-07-31 Merck Sharp & Dohme Corp. Methods for treating intrapulmonary infections
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US20140274994A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Stabilizing ceftolozane
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN104140427A (zh) * 2014-07-05 2014-11-12 湖南华腾制药有限公司 一种四氢吡唑并[1,5-a]嘧啶的制备方法
CN107922435B (zh) * 2015-09-08 2022-05-17 桑多斯股份公司 由7-氨基头孢烷酸(7-aca)制备头孢洛扎的方法
CN107586305A (zh) * 2017-06-23 2018-01-16 浙江惠迪森药业有限公司 一种β‑内酰胺类化合物羧基及羟基保护基脱除方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194432A (en) * 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA1293719C (en) * 1986-09-22 1991-12-31 Takao Takaya Cephem compounds and processes for preparation thereof
US5210080A (en) * 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US5663163A (en) * 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
IE63094B1 (en) * 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
US5173485A (en) * 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
GB8905301D0 (en) * 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR910015587A (ko) * 1990-02-27 1991-09-30 후지사와 토모키치로 세펨 화합물
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤
AUPN955596A0 (en) * 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
JP4448821B2 (ja) * 2002-10-30 2010-04-14 アステラス製薬株式会社 セフェム化合物
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE602004026451D1 (de) * 2003-09-18 2010-05-20 Astellas Pharma Inc Cephem-verbindungen

Also Published As

Publication number Publication date
NZ529887A (en) 2005-05-27
JP2004529172A (ja) 2004-09-24
ES2254671T3 (es) 2006-06-16
CN1522259A (zh) 2004-08-18
CA2446099A1 (en) 2002-11-14
NO20034824D0 (no) 2003-10-29
KR20030090794A (ko) 2003-11-28
WO2002090364A1 (en) 2002-11-14
TWI224599B (en) 2004-12-01
ATE318269T1 (de) 2006-03-15
EP1392704A1 (en) 2004-03-03
JP4251873B2 (ja) 2009-04-08
DE60209341T2 (de) 2006-08-03
RU2003134629A (ru) 2005-06-10
US7179801B2 (en) 2007-02-20
PL366507A1 (en) 2005-02-07
HUP0304042A2 (hu) 2004-04-28
MXPA03010002A (es) 2004-06-30
NO20034824L (no) 2003-12-29
DE60209341D1 (de) 2006-04-27
EP1392704B1 (en) 2006-02-22
US20040248875A1 (en) 2004-12-09
BR0209452A (pt) 2004-12-14

Similar Documents

Publication Publication Date Title
AR033300A1 (es) Compuestos de cefem
BRPI0315188B8 (pt) composto e composição farmacêutica
AR045768A1 (es) Compuestos de cefem y sus sales farmaceuticamente aceptables
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
DE69827236D1 (en) Matrix-metalloproteinase-hemmer
UY27368A1 (es) Nuevos compuestos
AP2001002241A0 (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents.
HUP9802814A2 (hu) Szelektív béta3 adrenergiás agonista hatású vegyületek, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
JPS55127384A (en) Novel chromone compound*its manufacture and drug composition containing it
KR927003520A (ko) 펩티딜(peptidyl) 유도체
CA2328780A1 (en) Dihydropyrimidines
MY114679A (en) Aroyl-piperidine derivatives
BR0111377A (pt) Derivados de tiofeno úteis como agentes anticancerìgenos
AR040473A1 (es) Derivados de aminoalcoholes, un procedimiento de preparacion, composicion farmaceutica y uso del compuesto para preparar medicamentos
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
ES8306160A1 (es) "procedimiento para preparar un nuevo compuesto de cefem".
MX9604483A (es) Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
AR035728A1 (es) Proceso perfeccionado para la sintesis de carbapenem
CO5140104A1 (es) Derivados de mevinolina y preparacion farmaceuticas que los contienen
BR0312798A (pt) Derivados de isotiazol úteis como agentes anticancerìgenos
BG100884A (en) Benzamide derivative, compositions containing said derivative and use thereof
AR044175A1 (es) Compuestos de cefemo

Legal Events

Date Code Title Description
FB Suspension of granting procedure